Ultimate Medicine is a Swiss preclinical dementia company, developing first-in-class small molecules targeting a novel gut microbiome-derived effector (MiDE). Pioneering MiDE pipelines, UM detected and characterised a previously unknown gut-brain pathway, implicated in cognitive decline.

The company’s lead program is an oral small-molecule inhibitor designed to block metabolite synthesis, thereby reducing systemic and brain exposure through natural clearance mechanisms. This therapeutic strategy is supported by a robust companion diagnostic program, which includes the validation of delta-valerobetaine as a novel neurodegenerative biomarker.

Headquartered in Zurich, Ultimate Medicine leverages an in-vivo approach to identify drug targets that precede neurodegeneration, aiming to preserve independence and quality of life for patients with Alzheimer’s and other age-related dementias.